Renalytix AI plc (NASDAQ:RNLX) shares gapped up prior to trading on Thursday . The stock had previously closed at $23.56, but opened at $24.50. Renalytix AI shares last traded at $24.19, with a volume of 8,786 shares changing hands.
RNLX has been the topic of a number of recent analyst reports. Investec lowered Renalytix AI from a “buy” rating to a “hold” rating in a research report on Tuesday, March 2nd. Zacks Investment Research lowered shares of Renalytix AI from a “hold” rating to a “sell” rating in a research note on Saturday, March 6th.
The stock’s 50-day moving average is $26.75 and its 200 day moving average is $18.36. The stock has a market capitalization of $871.78 million and a PE ratio of -147.25.
Renalytix AI (NASDAQ:RNLX) last posted its quarterly earnings data on Tuesday, March 2nd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.05). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $1.70 million. As a group, sell-side analysts forecast that Renalytix AI plc will post -0.23 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of RNLX. Pinnacle Associates Ltd. raised its stake in shares of Renalytix AI by 39.8% in the 4th quarter. Pinnacle Associates Ltd. now owns 34,440 shares of the company’s stock valued at $551,000 after buying an additional 9,800 shares in the last quarter. Polar Capital LLP bought a new stake in Renalytix AI during the 3rd quarter worth approximately $1,219,000. Gofen & Glossberg LLC IL lifted its holdings in Renalytix AI by 7.2% during the 4th quarter. Gofen & Glossberg LLC IL now owns 122,450 shares of the company’s stock worth $1,959,000 after buying an additional 8,250 shares in the last quarter. Pentwater Capital Management LP acquired a new position in Renalytix AI during the 3rd quarter worth $2,188,000. Finally, Silverarc Capital Management LLC acquired a new position in Renalytix AI during the 4th quarter worth $2,260,000. 13.61% of the stock is owned by institutional investors and hedge funds.
About Renalytix AI (NASDAQ:RNLX)
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score.
Receive News & Ratings for Renalytix AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix AI and related companies with MarketBeat.com's FREE daily email newsletter.